<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01324076</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000697324</org_study_id>
    <secondary_id>CRUK-TACE-2</secondary_id>
    <secondary_id>UCL-07130</secondary_id>
    <secondary_id>EU-21108</secondary_id>
    <secondary_id>CRUK-HE3005</secondary_id>
    <secondary_id>EUDRACT-2008-005073-36</secondary_id>
    <secondary_id>CRUK-13136</secondary_id>
    <secondary_id>ISRCTN-93375053</secondary_id>
    <secondary_id>CTA-20363/0272/001</secondary_id>
    <secondary_id>BAYER-CRUK-TACE-2</secondary_id>
    <secondary_id>BIOCOM-UK-CRUK-TACE-2</secondary_id>
    <nct_id>NCT01324076</nct_id>
  </id_info>
  <brief_title>Transarterial Chemoembolization Using Doxorubicin Beads With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery</brief_title>
  <official_title>TACE-2: A Randomized Placebo-Controlled, Double Blinded, Phase III Trial of Sorafenib in Combination With Transarterial Chemoembolization in Hepatocellular Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop&#xD;
      the growth of cancer cells, either by killing the cells or by stopping them from dividing.&#xD;
      Chemoembolization kills tumor cells by carrying drugs directly into the tumor and blocking&#xD;
      the blood flow to the tumor. Sorafenib tosylate may stop the growth of tumor cells by&#xD;
      blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.&#xD;
      It is not yet known whether transarterial chemoembolization using doxorubicin-eluting beads&#xD;
      is more effective when given with or without sorafenib tosylate in treating patients with&#xD;
      liver cancer that cannot be removed by surgery.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying giving transarterial chemoembolization&#xD;
      using doxorubicin-eluting beads and sorafenib tosylate to see how well it works compared with&#xD;
      giving transarterial chemoembolization using doxorubicin-eluting beads and a placebo in&#xD;
      treating patients with liver cancer that cannot be removed by surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine whether the addition of sorafenib tosylate to transarterial&#xD;
           chemoembolization (TACE) with doxorubicin-eluting beads, compared to TACE alone,&#xD;
           prolongs progression-free survival of patients with unresectable hepatocellular&#xD;
           carcinoma.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To determine if adding sorafenib tosylate to TACE prolongs overall survival of these&#xD;
           patients.&#xD;
&#xD;
        -  To determine if the sorafenib tosylate regimen prolongs time to progression in these&#xD;
           patients.&#xD;
&#xD;
        -  To determine acceptable toxicity related to the sorafenib tosylate regimen in these&#xD;
           patients.&#xD;
&#xD;
        -  To determine the effects of the sorafenib tosylate regimen on disease response, in terms&#xD;
           of complete response, partial response, or stable disease, in these patients.&#xD;
&#xD;
        -  To determine the effects of the sorafenib tosylate regimen on quality of life of these&#xD;
           patients.&#xD;
&#xD;
        -  To determine if treatment with the sorafenib tosylate regimen reduces the frequency for&#xD;
           repeat TACE as measured by number of TACE procedures performed in 12 months.&#xD;
&#xD;
        -  To establish a blood sample bank linked to this study for biomarker research (proteomic&#xD;
           and genomic analysis).&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to randomizing&#xD;
      centers and serum alpha-fetoprotein levels (&lt; 400 ng/mL vs ≥ 400 ng/mL). Patients are&#xD;
      randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive oral sorafenib tosylate twice daily in the absence of disease&#xD;
           progression or unacceptable toxicity. Beginning within 2-5 weeks after start of&#xD;
           sorafenib tosylate, patients undergo transarterial chemoembolization (TACE) with&#xD;
           doxorubicin-eluting beads. Patients may undergo additional sessions of TACE with&#xD;
           doxorubicin-eluting beads, in the absence of complete devascularization of the tumor(s)&#xD;
           (as assessed by follow-up contrast enhanced scan).&#xD;
&#xD;
        -  Arm II: Patients receive oral placebo twice daily in the absence of disease progression&#xD;
           or unacceptable toxicity. Beginning within 2-5 weeks after start of placebo, patients&#xD;
           undergo TACE with doxorubicin-eluting beads as in arm I. Patients with disease&#xD;
           progression may cross over to the sorafenib tosylate arm at the discretion of the&#xD;
           treating clinician and are followed for survival.&#xD;
&#xD;
      Blood samples may be collected at baseline and periodically for pharmacogenetic and&#xD;
      pharmacokinetic studies. Patients complete EORTC QoL questionnaire (QLQ-C30) version 3 and&#xD;
      EORTC QLQ-HCC18 (a site-specific module for HCC) at baseline and periodically during the&#xD;
      study.&#xD;
&#xD;
      After completion of study therapy, patients are followed up periodically for 1 year.&#xD;
&#xD;
      Peer Reviewed and Funded or Endorsed by Cancer Research UK.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2010</start_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control (complete or partial response or stable disease)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">412</enrollment>
  <condition>Liver Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin-eluting beads</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sorafenib tosylate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacogenomic studies</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed hepatocellular carcinoma (HCC) OR meets the&#xD;
             American Association for the Study of Liver Diseases (AASLD) criteria for diagnosis of&#xD;
             HCC&#xD;
&#xD;
               -  Unresectable disease&#xD;
&#xD;
               -  Not amenable to liver transplantation&#xD;
&#xD;
          -  At least one uni-dimensionally measurable lesion according to the RECIST criteria by&#xD;
             CT scan or MRI&#xD;
&#xD;
          -  Child-Pugh A (score ≤ 6) and no Child-Pugh cirrhosis C or B (score ≥ 7)&#xD;
&#xD;
          -  No ascites refractory to diuretic therapy&#xD;
&#xD;
          -  No documented occlusion of the hepatic artery or main portal vein&#xD;
&#xD;
          -  No extrahepatic metastasis or hepatic encephalopathy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  Hemoglobin ≥ 9 g/L&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1.5 x 10^9/L&#xD;
&#xD;
          -  Platelet count ≥ 60,000/μL&#xD;
&#xD;
          -  Bilirubin ≤ 50 μmol/L&#xD;
&#xD;
          -  Alkaline phosphatase &lt; 4 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT &lt; 5 times ULN&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
          -  Amylase and lipase &lt; 2 times ULN&#xD;
&#xD;
          -  INR ≤ 1.5&#xD;
&#xD;
          -  LVEF ≥ 45%&#xD;
&#xD;
          -  Able to swallow oral medication&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during study and for 3 months after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  No history of bleeding within the past 4 weeks&#xD;
&#xD;
          -  No contraindications for hepatic embolization procedures, including portosystemic&#xD;
             shunt, hepatofugal blood flow, or known severe atheromatosis&#xD;
&#xD;
          -  No hypersensitivity to intravenous contrast agents&#xD;
&#xD;
          -  No active clinically serious infection &gt; grade 2 (NCI-CTC version 4)&#xD;
&#xD;
          -  No known history of HIV infection&#xD;
&#xD;
          -  No history of second malignancy except non-melanotic skin cancer or cervical carcinoma&#xD;
             in situ or malignancy treated with curative intent with &gt; 3 years without relapse&#xD;
&#xD;
          -  No evidence of severe or uncontrolled disease including any of the following:&#xD;
&#xD;
               -  Systemic disease&#xD;
&#xD;
               -  Cardiac arrhythmias (requiring anti-arrhythmic therapy or pacemaker)&#xD;
&#xD;
               -  Hypertension&#xD;
&#xD;
               -  NYHA class III or IV congestive cardiac failure&#xD;
&#xD;
               -  Myocardial infarction within the past 6 months&#xD;
&#xD;
               -  Laboratory finding that, in the view of the Investigator, makes it undesirable&#xD;
                  for the patient to participate in the trial&#xD;
&#xD;
          -  No psychiatric or other disorder likely to impact on informed consent&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  At least 4 weeks since prior and no concurrent investigational therapy&#xD;
&#xD;
          -  No prior embolization, systemic therapy, or radiotherapy for HCC&#xD;
&#xD;
          -  No major surgery within the past 4 weeks&#xD;
&#xD;
          -  No ablative therapy (radiofrequency ablation or percutaneous ethanol injection) for&#xD;
             HCC&#xD;
&#xD;
               -  Patients with untreated target lesion(s) and ablation occurred &gt; 6 weeks prior to&#xD;
                  study entry allowed&#xD;
&#xD;
          -  No concurrent rifampicin or St. John wort&#xD;
&#xD;
          -  No concurrent bone marrow transplant or stem cell rescue&#xD;
&#xD;
          -  No concurrent bevacizumab or drugs that target VEGF or VEGF receptors&#xD;
&#xD;
          -  No other concurrent anticancer chemotherapy, immunotherapy, hormone therapy, or&#xD;
             molecular therapy except bisphosphonates&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tim Meyer, MD, BSc, MRCP, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Free Hospital NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-121-472-1311</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bristol Royal Infirmary</name>
      <address>
        <city>Bristol</city>
        <state>England</state>
        <zip>BS2 8HW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-117-923-0000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aintree University Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>England</state>
        <zip>L9 7AL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-151-525-5980</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-20-7794-0500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-20-3299-9000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Marsden - London</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-20-7352-8171</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen's Medical Centre</name>
      <address>
        <city>Nottingham</city>
        <state>England</state>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-115-924-9924</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <state>England</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-23-8079-8751</phone>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <study_first_submitted>March 25, 2011</study_first_submitted>
  <study_first_submitted_qc>March 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2011</study_first_posted>
  <last_update_submitted>May 12, 2011</last_update_submitted>
  <last_update_submitted_qc>May 12, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2011</last_update_posted>
  <keyword>adult primary hepatocellular carcinoma</keyword>
  <keyword>localized unresectable adult primary liver cancer</keyword>
  <keyword>advanced adult primary liver cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

